Blog

Winan van Houdt: Wrapping up the annual CTOS meeting in San Diego

Winan van Houdt/eventscribe.net

Nov 17, 2024, 12:14

Winan van Houdt: Wrapping up the annual CTOS meeting in San Diego

Winan van Houdt, Surgical Oncologist at Antoni van Leeuwenhoek/Netherlands Cancer Institute, shared a post on LinkedIn:

“Wrapping up the annual Connective Tissue Oncology Society meeting in San Diego:

1) Presenting an update on our international EORTC – European Organisation for Research and Treatment of Cancer STRASS2/STREXIT2 study – now half of all patients are randomized (125/250), of which most in Europe but now also more and more patients in Japan, Australia, Canada and US.

2) Chairing the Session ‘the sarcoma of the year’ Dedifferentiated Liposarcoma where the Brightline study was presented for the first time evaluating Brigamedlin versus doxorubicin – unfortunately no significant difference, but clear responders amongst the Brigamedlin patients. Hopefully, we get the chance to further explore this drug on a different setting

3) Mentoring in the sunrise mentorship session and outside to help others developing their practice and careers

4) Meeting many old and new friends, getting inspired to set up new trials and learn form the best practices from each other.”

Winan van Houdt: Wrapping up the annual CTOS meeting in San Diego

More posts featuring Winan van Houdt.

Winan van Houdt is a surgical oncologist at Antoni van Leeuwenhoek/Netherlands Cancer Institute, specializing in rare cancers such as GIST, soft tissue sarcomas (retroperitoneal, intra-abdominal, and extremity), melanoma, desmoid tumors, and non-melanoma skin cancers.

He serves as the Program Coordinator for Rare Cancers at the Netherlands Cancer Institute and chairs the Soft Tissue and Bone Sarcoma Group (STBSG) at the EORTC. Van Houdt is also a member of the Scientific Steering Committee for the Sarcoma Track at ESMO 2024.